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Abstract
Background Management of diabetes in elderly patients
is complicated by the elevated risk of insulin-induced hy-
poglycaemia. This is the first study to report the pharma-
codynamic and pharmacokinetic characteristics of
IDegAsp (insulin degludec [IDeg]/insulin aspart [IAsp]), a
soluble co-formulation of a long-acting basal insulin ana-
logue (IDeg) and a rapid-acting insulin analogue (IAsp) in
a single injection, in elderly and younger adult subjects
with type 1 diabetes using a glucose clamp.
Methods In this randomised, single-centre, double-blind,
single-dose (SD), two-period, crossover trial, 15 elderly
subjects (aged C65 years) and 13 younger adults (aged
18–35 years) with type 1 diabetes were randomly assigned
to two SD administrations of 0.5 U/kg IDegAsp or biphasic
insulin aspart 30 (control) followed by a 26-h euglycaemic
glucose clamp and 120-h pharmacokinetic blood sampling.
The glucose infusion rate (GIR) profiles were extrapolated
to simulated steady-state (SS) conditions using pharmaco-
dynamic models.
Results IDegAsp GIR profiles showed a distinct peak
and rapid onset of action from IAsp followed by a
separate and flat basal action from IDeg. Mean 24-h area
under the GIR curve was similar in elderly subjects vs.
younger adults (mean ratio 1.01 [95 % confidence interval
0.69–1.47]). Simulated SS pharmacodynamic profiles with
once-daily IDegAsp showed a parallel upshift in GIR
profiles vs. SD profiles. The shape of the IDegAsp phar-
macodynamic profile was retained with twice-daily dosing
under simulated SS conditions. IDegAsp was well
tolerated.
Conclusions The distinct prandial and basal pharmaco-
dynamics of IDegAsp observed in younger adults were
preserved in elderly subjects with type 1 diabetes. The
glucose-lowering effect of IDegAsp was similar in elderly
subjects and younger adults with type 1 diabetes.
Key points
This is the first study to demonstrate the
pharmacodynamic and pharmacokinetic
characteristics of insulin degludec/insulin aspart in
elderly subjects vs. younger adult subjects with type
1 diabetes using a glucose clamp.
In this study, the distinct prandial and basal
pharmacodynamic properties of insulin degludec/
insulin aspart reported in younger adults were
preserved in elderly subjects with type 1 diabetes.
The glucose infusion rate profiles in both elderly
subjects younger adult subjects with type 1 diabetes
demonstrate a distinct peak action owing to the
prandial insulin aspart component, followed by a
sustained basal action owing to the long-acting
insulin degludec component.
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1 Introduction
Management of diabetes in the elderly can be multifaceted
owing to the increased frequency of co-morbidities and
chronic disorders and the heterogeneous nature of this
population compared with younger adults with diabetes [1].
This added complexity also heightens the risk of insulin-
induced hypoglycaemia associated with higher morbidity
and mortality, especially in elderly subjects at advanced
stages of the disease and those receiving multiple
medications [2, 3].
Insulin degludec (IDeg) is a new-generation, long-acting
basal insulin analogue [4, 5]. The long-acting pharma-
cokinetic and pharmacodynamic properties of IDeg ob-
served in younger adults with type 1 diabetes (T1DM) also
have been shown in elderly subjects [6]. Because of a
unique mechanism of protraction, IDeg can be combined
with the rapid-acting prandial insulin analogue, insulin
aspart (IAsp) [7], in insulin degludec/insulin aspart (IDe-
gAsp), resulting in a soluble co-formulation with 70 %
IDeg and 30 % IAsp [8]. IDegAsp is the first combination
product to include a long-acting basal insulin analogue,
providing both basal insulin coverage and a prandial in-
sulin bolus in a single injection [7].
IDegAsp is recommended for the treatment of diabetes
in adults and can be administered once or twice daily (BID)
with the main meal(s) [8]. When taken once daily (OD), the
patient can change the time of IDegAsp administration as
needed, provided it is dosed with the largest meal of the
day [8].
The distinct basal and prandial characteristics of the
IDeg and IAsp components of IDegAsp, which are pre-
served at steady state (SS) in subjects with T1DM [9], help
to reduce the risk of hypoglycaemia compared with stan-
dard premix insulins such as biphasic insulin apart 30
(BIAsp 30) [10]. However, the need remains to determine
the pharmacodynamic profile of IDegAsp in patients of
different ages, and, similar to the study with IDeg [6], such
data are valuable for clinical practice, as well as required
by the regulatory bodies. Thus, the primary objective of
this study was to investigate the pharmacodynamic profiles
of IDegAsp and BIAsp 30 in elderly subjects (aged
C65 years) and younger adult subjects (aged 18–35 years)
with T1DM.
2 Materials and Methods
2.1 Study Design
This was a randomised, single-centre (Department of In-
ternal Medicine, Division of Endocrinology and Nuclear
Medicine, University of Graz, Auenbruggerplatz 15, Graz,
Austria), double-blind, single-dose, two-period, crossover
trial in subjects with T1DM (Clinical trials.gov number:
NCT01174303). Before initiation of the trial, the protocol,
consent form and subject information sheet were reviewed
and approved by appropriate authorities and the Indepen-
dent Ethics Committee of the Medical University of Graz
(Ethikkommission der Medizinischen Universita¨t Graz)
according to local regulations. The trial was performed
according to the Declaration of Helsinki [11] and its
amendments and Good Clinical Practice as defined by the
International Conference on Harmonisation [12]. Subjects
were informed of the risks and benefits of the trial and that
they could withdraw from the trial at any time for any rea-
son. Consent was obtained in writing before any trial-related
activities, and the investigator retained the consent forms.
2.2 Study Population
Subjects were men and women aged C65 years (elderly
group) or aged 18–35 years (younger adult group) with
T1DM for C12 months and a fasting C-peptide level
\0.3 nmol/L. Other key inclusion criteria included sub-
jects who had been treated with insulin (\1.2 IU/kg/day)
for C12 months, body mass index (BMI) of 18.0–28.0
kg/m2 (inclusive) and glycosylated haemoglobin of
B10.0 %. Key exclusion criteria were the same as in a
previous study [6] and included smoking, recurrent severe
hypoglycaemia (more than one severe hypoglycaemic
event during the last 12 months), hypoglycaemic
unawareness and hospitalisation for diabetic ketoacidosis
during the previous 6 months.
2.3 Study Procedures
Subjects were randomly assigned to two single-dose ad-
ministrations of 0.5 U/kg IDegAsp or BIAsp 30 at two
separate visits (BIAsp 30 was included primarily as a
control for differentiation between drug- and population-
related differences in pharmacokinetic and pharmacody-
namic properties, in case differences between age groups
were observed for IDegAsp). The trial consisted of 10
visits: a screening visit (Visit 1), two treatment periods
(Visits 2–5 and Visits 6–9) and a follow-up visit (Visit 10).
At each of the two dosing visits, subjects remained hos-
pitalised for 48 h following product administration.
2.4 Euglycaemic Glucose Clamp Procedure
The pharmacodynamic effects of IDegAsp were evaluated
using a 26-h euglycaemic clamp procedure (target blood
glucose 5.5 mmol/L, [100 mg/dL]), beginning after dosing
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during Visit 2 (treatment period 1) and Visit 6 (treatment
period 2), similar to the approach described previously [6]
(see Supporting information for details). The clamp pro-
cedure was terminated early if plasma glucose levels con-
sistently exceeded 11.1 mmol/L (200 mg/dL) without any
glucose infusion in the previous 30 min.
2.5 Pharmacokinetic Sampling
Following IDegAsp administration, serum concentrations
of IAsp and IDeg were analysed separately. Blood samples
were collected at the times specified in Table S1. Serum
IAsp concentrations after IDegAsp and BIAsp 30 admin-
istration were analysed at the same time points until 12 h
and 24 h after dosing, respectively. IDeg concentrations
were analysed until 120 h post-dosing. Serum IDeg and
serum IAsp concentrations were measured using a
validated, specific, sandwich enzyme-linked immunosor-
bent assay.
2.6 Safety Assessments
Safety endpoints comprised adverse events, including local
injection-site reactions, laboratory safety variables, physi-
cal examination, vital signs, electrocardiogram and hypo-
glycaemic episodes (defined as ‘confirmed’ when they
were either ‘severe’ as defined by the American Diabetes
Association [13] or verified by a plasma glucose level of
\3.1 mmol/L [56 mg/dL]).
2.7 Data and Statistical Analysis
No formal sample size calculations for this trial were
performed. The pharmacodynamic response of IDegAsp
was determined by calculating the area under the curve
(AUC)GIR,0–24,SD using the linear trapezoidal technique on
interpolated data points. The log-transformed
AUCGIR,0–24,SD for the IDegAsp treatment was analysed
using a linear model with age group (elderly/young adult)
and treatment period (period 1/2) as fixed effects. Glucose
infusion rate (GIR) data were smoothed using the Loess
smoothing technique using a fixed smoothing parameter of
0.1 for the bolus (the first 6 h) and 0.25 for the basal (from
6 h onwards) part of the curve with combined smoothing.
GIR data were smoothed to show the mean GIR profiles,
excluding fluctuations caused by the clamp method.
Smoothed data may not always start at 0 as each point in
the smoothed plot is computed as a weighted average of the
values before and after the data point, giving most weight
to the closest neighbouring data points. Only data after the
injection time point are included (non-zero positive values)
and therefore the plot does not start at 0 (see ‘‘Results’’).
All pharmacokinetic and pharmacodynamic endpoints and
safety endpoints were analysed based on the full analysis
set and the safety analysis set, respectively. Safety end-
points were summarised using descriptive statistics.
2.8 Pharmacodynamic Modelling
To simulate SS pharmacodynamic profiles from this single-
dose study, a population pharmacodynamic model was
used to describe the GIR response for IDegAsp. The model
used here has previously been described [9] and a full
description of the pharmacodynamic modelling is provided
in the supplementary information.
3 Results
3.1 Baseline Characteristics
A total of 28 (15 elderly; 13 younger) subjects were
randomised to receive IDegAsp or BIAsp 30. All subjects
completed the trial and no subject withdrew or was
withdrawn (full analysis set 28; safety analysis set 28)
(Fig. S1).
Apart from age and, therefore, duration of diabetes,
baseline characteristics were similar for both age groups.
The mean duration of diabetes was approximately 21 years
longer for elderly subjects compared with the younger
adults (Table 1).
3.2 Pharmacodynamics
In elderly and younger adult subjects, the GIR profiles
showed rapid onset of action and a distinct peak from the
IAsp component followed by a separate and flat basal ac-
tion of the long-acting IDeg component, which was sus-
tained for the duration of the clamp (see Fig. 1a). The mean
AUCGIR,0–24h,SD for IDegAsp was similar for elderly and
younger adult subjects (mean ratio elderly/younger adults
1.01, 95 % confidence interval [CI] 0.69–1.47). There were
no marked differences between the age groups across the
secondary pharmacodynamic endpoints (Table 2).
This study was performed as a single-dose trial but it is
possible to extrapolate the comparison of IDegAsp OD
GIR profiles to the SS setting. Simulated SS pharmaco-
dynamic profiles for subjects in both age groups are shown
in Fig. 1b, where an upshift in the simulated GIR profile at
SS was apparent compared with the single-dose profiles.
The onset of action and shape of the single-dose GIR
profiles over the first 4 h were similar for IDegAsp and
BIAsp 30 in the elderly subjects, although the maximum
GIR (GIRmax,SD) appeared to be lower for IDegAsp com-
pared with BIAsp 30 (Fig. 2a). Afterwards, BIAsp 30 GIR
steadily decreased and reached zero 18–20 h after
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injection. In contrast, the mean GIR for IDegAsp rapidly
declined from GIRmax,SD until approximately 7 h post-
dosing, after which GIR continued to decline slowly at a
constant and sustained rate for the remainder of the clamp.
Graphs are shown for smoothed (Fig. 2a) and raw (Fig. 2b)
mean GIR profiles, the shapes of the smoothed and raw
profiles are comparable. The GIR profiles for elderly and
younger adults for IDegAsp or BIAsp 30 were consistent
Table 1 Baseline
characteristics




No. of subjects 15 13
Age, years 68.2 (65.1; 79.2) 25.4 (19.3; 33.3)
BMI, kg/m2 25.2 (19.3; 28.7) 23.2 (20.6; 25.9)
Race
White, n 15 13
Sex
Female, n 6 4
Male, n 9 9
Duration of diabetes, years 34.4 (2.8; 65.1) 13.0 (6.6; 26.1)
HbA1c, % 7.5 (6.4; 9.6) 7.4 (5.5; 9.2)
Fasting C-peptide, nmol/L 0.02 (0.00; 0.08) 0.01 (0.00; 0.02)
BMI body mass index, HbA1c glycosylated haemoglobin
a
b
Fig. 1 a Mean glucose infusion
rate profiles following a single
dose (0.5 U/kg) of insulin
degludec/insulin aspart in
subjects of two different age
groups with type 1 diabetes.
b Simulated mean glucose
infusion rate profiles of insulin
degludec/insulin aspart (0.5 U/
kg) at steady state in elderly and
younger adult subjects with type
1 diabetes
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with the profiles previously reported for adults with T1DM
[14]. However, caution should be taken when comparing
the effect of single doses of IDegAsp and BIAsp 30 di-
rectly. This is because of the long-acting nature of IDeg,
the basal component in IDegAsp, further discussed in
Sect. 4 and pharmacodynamic variables at SS or after a
single dose for IDegAsp or BIAsp 30 for elderly and
younger adult subjects are shown in Table 3.
A simulated model of pharmacodynamic response to
IDegAsp BID at SS in both age groups indicated that
distinct IAsp and IDeg peaks in IDegAsp are retained
following each dose (Fig. 3). The profile shapes over each
Table 2 Pharmacodynamic
endpoints in elderly and
younger adult subjects with type




Elderly subjects Younger adult subjects
No. of subjects 15 13
AUCGIR, 0–24h,SD, mg/kg (CV, %)
a 1794 (62) 1786 (28)
AUCGIR, 0–6h,SD, mg/kg, (CV, %)
a 909 (45) 1001 (25)
GIRmax,SD, mg/(kg min), (CV, %)
a 3.9 (53) 4.4 (30)
tGIRmax,SD, h, (CV, %)
b 2.7 (31) 2.2 (35)
AUC area under the curve. CV coefficient of variation, GIR glucose infusion rate, max maximum, SD single





Fig. 2 a Mean glucose infusion
rate profile following a single
dose (0.5 U/kg) of insulin
degludec/insulin aspart
(IDegAsp) or biphasic insulin
apart 30 (BIAsp 30) in elderly
subjects with type 1 diabetes.
b Raw mean glucose infusion
rate profile
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dosing interval are similar to those observed with IDegAsp
OD simulations at SS (Fig. 1b).
3.3 Pharmacokinetics
The total exposure of IAsp in IDegAsp (AUCIAsp,0–12h,SD)
was statistically significantly higher in elderly compared
with younger adult subjects; the estimated mean age
group ratio (elderly subjects/younger adults) was 1.37
(95 % CI 1.01–1.87). In a sensitivity analysis that ex-
cluded one subject (subject 20) with physiologically im-
plausible high IAsp concentrations, the difference
between elderly subjects and younger adults was not
statistically significant (estimated mean age group ratio
[elderly subjects/younger adults]) for IAsp (1.27; 95 % CI
0.97–1.65). The total exposure of IDeg in IDegAsp
(AUCIDeg,0–120h,SD) was not significantly different be-
tween the two age groups, with an estimated mean age
group ratio (elderly subjects/younger adults) of 1.24
(95 % CI 0.90–1.70). Without the outlier, the ratio for
IDeg was 1.12 (95 % CI 0.89–1.40).
The mean concentration–time profiles for IAsp in
IDegAsp (subject 20 excluded) were similar for elderly and
younger adult subjects (data not shown). In the sensitivity
analysis (subject 20 excluded), maximum serum concen-
tration for IAsp in IDegAsp was 305 pmol/L in the elderly
subjects and 221 pmol/L in the younger adults.
3.4 Safety
IDegAsp was well tolerated in both elderly and younger
adult subjects and no safety issues were identified during
the trial. There were no episodes of severe hypoglycaemia.
4 Discussion
This study was the first to evaluate pharmacodynamic and
pharmacokinetic properties of IDegAsp using a eugly-
caemic clamp procedure in elderly and younger adult
subjects with T1DM. The pharmacodynamic profiles of
IDegAsp as assessed by AUCGIR,0–24h,SD were similar for
elderly and younger adult subjects and IDegAsp was well
tolerated in the study population. The mean GIR profiles of
IDegAsp reflected the different and distinct actions of its
bolus and basal insulin components, as shown by a rapid
increase after dosing until GIRmax,SD followed by a rapid
decline, after which the GIR stabilised for the remainder of
the clamp period. This was also previously demonstrated
during a euglycaemic clamp procedure with increasing
IDegAsp doses [15]. It is noteworthy that in the present
study the variability in the AUCGIR,0–24,SD between sub-
jects seemed greater in the elderly subjects than in the
younger adults based on the standard deviation (Table 3).
This may be because of the heterogeneity of insulin
Table 3 Pharmacodynamic parameters in elderly and younger adult subjects with type 1 diabetes at steady state (SS) or following a single-dose
(SD) of insulin degludec/insulin aspart (IDegAsp) or biphasic insulin aspart 30 (BIAsp 30)













AUCGIR, 0–24h,SD, mg/kg (CV, %) 1794 (62) 1786 (28) 2550 (70) 2427 (30) 2349 (57) 2375 (42)
GIRmax,SD, mg/(kg min) (CV, %) 3.9 (53) 4.4 (30) 4.7 (57) 5.1 (30) 4.9 (46) 6.1 (47)
AUC area under the curve, CV coefficient of variation, GIR glucose infusion rate
Fig. 3 Simulated mean glucose
infusion rate profiles of insulin
degludec/insulin aspart
administered twice daily
(0.25 U/kg per dose) at steady
state in elderly and younger
adult subjects with type 1
diabetes
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resistance among the elderly, as insulin resistance can in-
crease with age [16].
The maximum GIR was lower after single doses of
IDegAsp compared with BIAsp 30 in elderly or younger
adult subjects. However, for BIAsp 30, GIR returned to
baseline values 18–22 h after injection, namely before the
next dose in a OD regimen. By comparison, a greater
glucose-lowering effect has been demonstrated with IDe-
gAsp at SS compared with a single dose [9] owing to the
long-acting nature of IDeg, which persists beyond a 24-h
dosing interval. At SS, the total and maximum glucose-
lowering effects for IDegAsp were comparable to BIAsp
30 in both populations (Table 3). As a basal insulin ana-
logue with a half-life extending beyond 24 h, IDeg
achieves SS in 2–3 days (defined as a serum concentration
reaching 90 % of the final plateau concentration and an
intake of a drug in dynamic equilibrium with its elimina-
tion) [17]. The longer duration of action provided by the
IDeg component in IDegAsp, compared with the pro-
taminated form of IAsp in BIAsp 30, shows that the long-
acting, flat and sustained basal insulin properties of IDeg
observed at SS [17] are preserved in IDegAsp. SS therefore
represents a more clinically relevant context in which to
investigate the pharmacodynamic profile of IDegAsp when
comparing this formulation with other insulins.
Modelling of simulated SS pharmacodynamic profiles in
this study showed a parallel upshift in GIR profiles under
simulated SS conditions compared with single-dose GIR
profiles. The GIR (including GIRmax) and the duration of
action of IDegAsp are higher and longer, respectively,
under simulated SS conditions compared with single-dose
profiles. The findings at simulated SS conditions are in
alignment with the results recently published for IDeg at
SS in patients with T1DM [6]. In the study by Korsatko
et al. [6] the long-acting properties of IDeg were compa-
rable in elderly subjects and in younger adults.
Because IDegAsp can be administered OD or BID,
pharmacodynamic profiles for both age groups were also
simulated at SS using an IDegAsp BID model, by dividing
the IDegAsp dose by two (0.25 U/kg BID). The basal
glucose-lowering effect (owing to the IDeg component)
was the same with OD or BID dosing because this is de-
pendent on total dose rather than on the dosing frequency
of IDegAsp. In contrast, as expected, the IAsp (bolus
component) peak was approximately half the size with
IDegAsp BID compared with IDegAsp OD. Similar results
were also observed in a previous study with IDegAsp in
adult subjects with T1DM [9].
In this study, the total exposure of both insulin com-
ponents of IDegAsp was found to be similar between
elderly subjects and younger adults (one subject with
implausibly high exposure concentrations was removed).
The mean concentration–time profiles were also similar
between both age groups, indicating that the absorption
properties of IDeg and IAsp observed in younger adults
are preserved in the elderly. Similar findings have also
been reported by Korsatko et al. [6] regarding the
properties of IDeg in elderly subjects vs. younger adults
at SS.
This study is the first of its type to report the prop-
erties of IDegAsp in the elderly population where the
management of diabetes is further complicated by ex-
isting co-morbidities. A strength of this study is the use
of a euglycaemic glucose clamp, which is considered as
the ‘gold standard’ in determining pharmacodynamic
properties of insulin [18]. The investigation of these
properties in only patients with T1DM enabled the
assessment of pharmacodynamic response under clamp
conditions without interference from endogenous insulin,
a potential complication and challenge when studying
subjects with type 2 diabetes. The main limitation of
this study is that the results are based on single-dose
administrations rather than performed at SS conditions.
While the simulated SS models are a valuable indicator
of IDegAsp in this setting, it is important to verify these
properties under clinical SS settings. In addition, the
study included a relatively small number of subjects and
larger-scale clinical trials with more patients and a
narrower range of age groups with IDegAsp are there-
fore warranted.
5 Conclusions
This study showed the distinct prandial and basal phar-
macodynamic properties of IDegAsp previously reported in
adults [9] and for treatment with IDeg [6] are preserved in
elderly subjects. The glucose-lowering profile of IDegAsp
over 24 h is preserved in elderly subjects with T1DM,
consisting of a distinct peak action owing to the prandial
IAsp component, in addition to the sustained long-acting
effect of IDeg. The single-dose GIR profile observed for
younger adults in this study was similar to those observed
previously and modelling of OD IDegAsp effects at SS
showed a slight upshift to a flatter profile owing to the IDeg
component. The basal glucose-lowering effect of IDegAsp
was retained under simulated SS conditions with BID
dosing of IDegAsp.
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